Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Biochim Biophys Acta ; 1825(1): 77-85, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22056543

ABSTRACT

In recent years, attention has focused on the biology and potential clinical importance of the CpG island methylator phenotype (CIMP) in colorectal cancer (CRC). While it is generally well accepted that etiologically and clinically distinct subgroups exist in this disease, a precise definition of CIMP remains to be established. Here, we summarize existing literature that documents the prevalence of CIMP in CRC, with particular attention to the various methods and definitions used to classify a tumor as CIMP positive. Through a systematic review on both case-series and population based studies, we examined only original research articles reporting on sporadic CRC and/or adenomas in unselected cases. Forty-eight papers published between January 1999 and August 2011 met the inclusion criteria. We describe the use of multiple gene panels, marker threshold values, and laboratory techniques which results in a wide range in the prevalence of CIMP. Because there is no universal standard or consensus on quantifying the phenotype, establishing its true prevalence is a challenge. This bottleneck is becoming increasingly evident as molecular pathological epidemiology continues to offer possibilities for clear answers regarding environmental risk factors and disease trends. For the first time, large, unselected series of cases are available for analysis, but comparing populations and pooling data will remain a challenge unless a universal definition of CIMP and a consensus on analysis can be reached, and the primary cause of CIMP identified.


Subject(s)
Colorectal Neoplasms/genetics , CpG Islands , DNA Methylation , Guidelines as Topic , Humans , Phenotype
2.
Cancer Prev Res (Phila) ; 5(3): 464-72, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22135045

ABSTRACT

Using a bioinformatics-based strategy, we set out to identify hypermethylated genes that could serve as biomarkers for early detection of colorectal cancer (CRC) in stool. In addition, the complementary value to a Fecal Immunochemical Test (FIT) was evaluated. Candidate genes were selected by applying cluster alignment and computational analysis of promoter regions to microarray-expression data of colorectal adenomas and carcinomas. DNA methylation was measured by quantitative methylation-specific PCR on 34 normal colon mucosa, 71 advanced adenoma, and 64 CRC tissues. The performance as biomarker was tested in whole stool samples from in total 193 subjects, including 19 with advanced adenoma and 66 with CRC. For a large proportion of these series, methylation data for GATA4 and OSMR were available for comparison. The complementary value to FIT was measured in stool subsamples from 92 subjects including 44 with advanced adenoma or CRC. Phosphatase and Actin Regulator 3 (PHACTR3) was identified as a novel hypermethylated gene showing more than 70-fold increased DNA methylation levels in advanced neoplasia compared with normal colon mucosa. In a stool training set, PHACTR3 methylation showed a sensitivity of 55% (95% CI: 33-75) for CRC and a specificity of 95% (95% CI: 87-98). In a stool validation set, sensitivity reached 66% (95% CI: 50-79) for CRC and 32% (95% CI: 14-57) for advanced adenomas at a specificity of 100% (95% CI: 86-100). Adding PHACTR3 methylation to FIT increased sensitivity for CRC up to 15%. PHACTR3 is a new hypermethylated gene in CRC with a good performance in stool DNA testing and has complementary value to FIT.


Subject(s)
Biomarkers, Tumor/genetics , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , DNA Methylation , Feces/chemistry , Nuclear Proteins/genetics , Adenoma/diagnosis , Adenoma/genetics , Case-Control Studies , Colon/metabolism , DNA, Neoplasm/genetics , Humans , Immunoenzyme Techniques , Mass Screening , Polymerase Chain Reaction , Promoter Regions, Genetic , ROC Curve , Rectum/metabolism
3.
Cancer Prev Res (Phila) ; 4(10): 1563-71, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21750209

ABSTRACT

Given the current increase in colorectal cancer screening, information on performance of screening tests is needed, especially in groups with a presumed lower test performance. We compared test performance of immunologic fecal occult blood testing (FIT) and pseudosigmoidoscopy with colonoscopy for detection of advanced adenomas in an average risk screening population. In addition, we explored the influence of gender, age, and location on test performance. FIT was collected prior to colonoscopy with a 50 ng/mL cutoff point. FIT results and complete colonoscopy findings were available from 329 subjects (mean age: 54.6 ± 3.7 years, 58.4% women). Advanced adenomas were detected in 38 (11.6%) of 329 subjects. Sensitivity for advanced adenomas of FIT and sigmoidoscopy were 15.8% (95% CI: 6.0-31.3) and 73.7% (95% CI: 56.9-86.6), respectively. No sensitivity improvement was obtained using the combination of sigmoidoscopy and FIT. Mean fecal hemoglobin in FIT positives was significantly lower for participants with only proximal adenomas versus those with distal ones (P = 0.008), for women versus men (P = 0.023), and for younger (<55 years) versus older (≥55 years) subjects (P = 0.029). Sensitivities of FIT were 0.0% (95% CI: 0.0-30.9) in subjects with only proximal versus 21.4% (95% CI: 8.3-41.0) in those with distal nonadvanced adenomas; 5.3% (95% CI: 0.0-26.0) in women versus 26.3% (95% CI: 9.2-51.2) in men; 9.5% (95% CI: 1.2-30.4) in younger versus 23.5% (95% CI: 6.8-49.9) in older subjects. Sigmoidoscopy had a significantly higher sensitivity for advanced adenomas than FIT. A single FIT showed very low sensitivity, especially in subjects with only proximal nonadvanced adenomas, in women, and in younger subjects. This points to the existence of "low" FIT performance in subgroups and the need for more tailored screening strategies.


Subject(s)
Adenoma/prevention & control , Colonoscopy , Colorectal Neoplasms/prevention & control , Mass Screening , Occult Blood , Sigmoidoscopy , Adenoma/diagnosis , Aged , Cohort Studies , Colorectal Neoplasms/diagnosis , Early Detection of Cancer , Female , Humans , Immunologic Tests , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity
4.
Clin Cancer Res ; 15(12): 3990-7, 2009 Jun 15.
Article in English | MEDLINE | ID: mdl-19509152

ABSTRACT

PURPOSE: The transcription factors GATA4 and GATA5 are involved in gastrointestinal development and are inactivated by promoter hypermethylation in colorectal cancer. Here, we evaluated GATA4/5 promoter methylation as potential biomarkers for noninvasive colorectal cancer detection, and investigated the role of GATA4/5 in colorectal cancer. EXPERIMENTAL DESIGN: Promoter methylation of GATA4/5 was analyzed in colorectal tissue and fecal DNA from colorectal cancer patients and healthy controls using methylation-specific PCR. The potential function of GATA4/5 as tumor suppressors was studied by inducing GATA4/5 overexpression in human colorectal cancer cell lines. RESULTS: GATA4/5 methylation was observed in 70% (63/90) and 79% (61/77) of colorectal carcinomas, respectively, and was independent of clinicopathologic features. Methylation frequencies in normal colon tissues from noncancerous controls were 6% (5 of 88, GATA4; P < 0.001) and 13% (13 of 100, GATA5; P < 0.001). GATA4/5 overexpression suppressed colony formation (P < 0.005), proliferation (P < 0.001), migration (P < 0.05), invasion (P < 0.05), and anchorage-independent growth (P < 0.0001) of colorectal cancer cells. Examination of GATA4 methylation in fecal DNA from two independent series of colorectal cancer patients and controls yielded a sensitivity of 71% [95% confidence interval (95% CI), 55-88%] and specificity of 84% (95% CI, 74-95%) for colorectal cancer detection in the training set, and a sensitivity of 51% (95% CI, 37-65%) and specificity of 93% (95% CI, 84-100%) in the validation set. CONCLUSIONS: Methylation of GATA4/5 is a common and specific event in colorectal carcinomas, and GATA4/5 exhibit tumor suppressive effects in colorectal cancer cells in vitro. GATA4 methylation in fecal DNA may be of interest for colorectal cancer detection.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma/diagnosis , Colorectal Neoplasms/diagnosis , DNA Methylation , GATA4 Transcription Factor/genetics , GATA5 Transcription Factor/genetics , Genes, Tumor Suppressor , Carcinoma/genetics , Cell Line, Tumor , Colorectal Neoplasms/genetics , CpG Islands/genetics , CpG Islands/physiology , Feces/chemistry , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Microsatellite Instability , Middle Aged , Promoter Regions, Genetic/genetics , Promoter Regions, Genetic/physiology , Retrospective Studies
5.
J Natl Cancer Inst ; 101(13): 916-27, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19535783

ABSTRACT

BACKGROUND: Identification of hypermethylated tumor suppressor genes in body fluids is an appealing strategy for the noninvasive detection of colorectal cancer. Here we examined the role of N-Myc downstream-regulated gene 4 (NDRG4) as a novel tumor suppressor and biomarker in colorectal cancer. METHODS: NDRG4 promoter methylation was analyzed in human colorectal cancer cell lines, colorectal tissue, and noncancerous colon mucosa by using methylation-specific polymerase chain reaction (PCR) and bisulfite sequencing. NDRG4 mRNA and protein expression were studied using real-time-PCR and immunohistochemistry, respectively. Tumor suppressor functions of NDRG4 were examined by colony formation, cell proliferation, and migration and invasion assays in colorectal cancer cell lines that were stably transfected with an NDRG4 expression construct. Quantitative methylation-specific PCR was used to examine the utility of NDRG4 promoter methylation as a biomarker in fecal DNA from 75 colorectal cancer patients and 75 control subjects. All P values are two-sided. RESULTS: The prevalence of NDRG4 promoter methylation in two independent series of colorectal cancers was 86% (71/83) and 70% (128/184) compared with 4% (2/48) in noncancerous colon mucosa (P < .001). NDRG4 mRNA and protein expression were decreased in colorectal cancer tissue compared with noncancerous colon mucosa. NDRG4 overexpression in colorectal cancer cell lines suppressed colony formation (P = .014), cell proliferation (P < .001), and invasion (P < .001). NDRG4 promoter methylation analysis in fecal DNA from a training set of colorectal cancer patients and control subjects yielded a sensitivity of 61% (95% confidence interval [CI] = 43% to 79%) and a specificity of 93% (95% CI = 90% to 97%). An independent test set of colorectal cancer patients and control subjects yielded a sensitivity of 53% (95% CI = 39% to 67%) and a specificity of 100% (95% CI = 86% to 100%). CONCLUSIONS: NDRG4 is a candidate tumor suppressor gene in colorectal cancer whose expression is frequently inactivated by promoter methylation. NDRG4 promoter methylation is a potential biomarker for the noninvasive detection of colorectal cancer in stool samples.


Subject(s)
Adenoma/chemistry , Biomarkers, Tumor/analysis , Carcinoma/chemistry , Colorectal Neoplasms/chemistry , DNA Methylation , Feces/chemistry , Genes, Tumor Suppressor , Intestinal Mucosa/chemistry , Muscle Proteins/analysis , Muscle Proteins/genetics , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/genetics , Adenoma/diagnosis , Adenoma/genetics , Adenoma/prevention & control , Adult , Aged , Biomarkers, Tumor/genetics , Carcinoma/diagnosis , Carcinoma/genetics , Carcinoma/prevention & control , Case-Control Studies , Cell Movement , Cell Proliferation , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , Colorectal Neoplasms/prevention & control , Early Detection of Cancer , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Invasiveness , Polymerase Chain Reaction , Prevalence , Promoter Regions, Genetic , RNA, Messenger/analysis , Retrospective Studies , Sensitivity and Specificity , Tumor Stem Cell Assay , Up-Regulation
6.
Cancer Res ; 69(11): 4691-9, 2009 Jun 01.
Article in English | MEDLINE | ID: mdl-19435926

ABSTRACT

We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma/diagnosis , Colorectal Neoplasms/diagnosis , DNA Methylation , Feces/chemistry , Glycoproteins/genetics , Aged , Aged, 80 and over , Algorithms , Biomarkers, Tumor/analysis , Caco-2 Cells , Carcinoma/genetics , Carcinoma/pathology , Case-Control Studies , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , DNA Methylation/physiology , DNA Mutational Analysis/methods , Early Detection of Cancer , Female , Glycoproteins/analysis , HCT116 Cells , HT29 Cells , Humans , Male , Middle Aged , Pilot Projects , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL